Epclusa FDA Approval History
Last updated by Judith Stewart, BPharm on April 6, 2020.
FDA Approved: Yes (First approved June 28, 2016)
Brand name: Epclusa
Generic name: sofosbuvir and velpatasvir
Dosage form: Tablets and Oral Pellets
Company: Gilead Sciences, Inc.
Treatment for: Hepatitis C
Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
Development Timeline for Epclusa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.